Table of Contents Author Guidelines Submit a Manuscript
Anesthesiology Research and Practice
Volume 2009 (2009), Article ID 827290, 9 pages
http://dx.doi.org/10.1155/2009/827290
Clinical Study

Tetrahydrocannabinol (Delta 9-THC) Treatment in Chronic Central Neuropathic Pain and Fibromyalgia Patients: Results of a Multicenter Survey

1Department of Anesthesiology, Intensive Care, Emergency Medicine and Pain Therapy, Kantonsspital Lucerne, 6000 Lucerne, Switzerland
2Department of Anesthesiology, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany
3Department of Anesthesiology and Pain Medicine, Swiss Paraplegic Center, 6207 Nottwil, Switzerland
4Department of Neuroscience, Algesiology and Pediatrics, 90419 Nuremberg, Germany

Received 20 April 2009; Revised 30 July 2009; Accepted 7 September 2009

Academic Editor: Thomas J. J. Blanck

Copyright © 2009 Janet Weber et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Freeman, “The treatment of neuropathic pain,” CNS Spectrums, vol. 10, no. 9, pp. 698–706, 2005. View at Google Scholar · View at Scopus
  2. T. Saarto and P. J. Wiffen, “Antidepressants for neuropathic pain,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD005454, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Bowsher, “Neurogenic pain syndromes and their management,” British Medical Bulletin, vol. 47, no. 3, pp. 644–666, 1991. View at Google Scholar · View at Scopus
  4. A. Calignano, G. La Rana, A. Giuffrida, and D. Piomelli, “Control of pain initiation by endogenous cannabinoids,” Nature, vol. 394, no. 6690, pp. 277–281, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Iversen, “Cannabis and the brain,” Brain, vol. 126, no. 6, pp. 1252–1270, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Mackie, “Cannabinoid receptors as therapeutic targets,” Annual Review of Pharmacology and Toxicology, vol. 46, pp. 101–122, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Rukwied, B. Gauter, M. Schley, and C. Konrad, “Cannabinoids—signal transduction and mode of action,” Schmerz, vol. 19, no. 6, pp. 528–534, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. J. M. Sullivan, “Cellular and molecular mechanisms underlying learning and memory impairments produced by cannabinoids,” Learning and Memory, vol. 7, no. 3, pp. 132–139, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Mechoulam and Y. Gaoni, “The absolute configuration of δ1-tetrahydrocannabinol, the major active constituent of hashish,” Tetrahedron Letters, vol. 8, no. 12, pp. 1109–1111, 1967. View at Google Scholar · View at Scopus
  10. T. Iuvone, G. Esposito, D. De Filippis, C. Scuderi, and L. Steardo, “Cannabidiol: a promising drug for neurodegenerative disorders?” CNS Neuroscience and Therapeutics, vol. 15, no. 1, pp. 65–75, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Baker and G. Pryce, “The endocannabinoid system and multiple sclerosis,” Current Pharmaceutical Design, vol. 14, no. 23, pp. 2326–2336, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Manzanares, M. D. Julian, and A. Carrascosa, “Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes,” Current Neuropharmacology, vol. 4, no. 3, pp. 239–257, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Baker, G. Pryce, G. Giovannoni, and A. J. Thompson, “The therapeutic potential of cannabis,” Lancet Neurology, vol. 2, no. 5, pp. 291–298, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. E. B. Russo, “Cannabinoids in the management of difficult to treat pain,” Therapeutics and Clinical Risk Management, vol. 4, no. 1, pp. 245–259, 2008. View at Google Scholar · View at Scopus
  15. M. Karst and S. Wippermann, “Cannabinoids against pain. Efficacy and strategies to reduce psychoactivity: a clinical perspective,” Expert Opinion on Investigational Drugs, vol. 18, no. 2, pp. 125–133, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. D. J. Rog, T. J. Nurmikko, and C. A. Young, “Oromucosal Δ9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial,” Clinical Therapeutics, vol. 29, no. 9, pp. 2068–2079, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Zajicek, P. Fox, H. Sanders et al., “Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial,” The Lancet, vol. 362, no. 9395, pp. 1517–1526, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. J. L. Croxford, “Therapeutic potential of cannabinoids in CNS disease,” CNS Drugs, vol. 17, no. 3, pp. 179–202, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. E. Woolridge, S. Barton, J. Samuel, J. Osorio, A. Dougherty, and A. Holdcroft, “Cannabis use in HIV for pain and other medical symptoms,” Journal of Pain and Symptom Management, vol. 29, no. 4, pp. 358–367, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. D. Gourlay, “Addiction and pain medicine,” Pain Research and Management, vol. 10, supplement A, pp. 38A–43A, 2005. View at Google Scholar · View at Scopus
  21. D. J. Buggy, L. Toogood, S. Maric, P. Sharpe, D. G. Lambert, and D. J. Rowbotham, “Lack of analgesic efficacy of oral δ-9-tetrahydrocannabinol in postoperative pain,” Pain, vol. 106, no. 1-2, pp. 169–172, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Clermont-Gnamien, S. Atlani, N. Attal, F. Le Mercier, F. Guirimand, and L. Brasseur, “The therapeutic use of D9-tetrahydrocannabinol (dronabinol) in refractory neuropathic pain,” Presse Medicale, vol. 31, no. 39, part 1, pp. 1840–1845, 2002. View at Google Scholar · View at Scopus
  23. M. Naef, M. Curatolo, S. Petersen-Felix, L. Arendt-Nielsen, A. Zbinden, and R. Brenneisen, “The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions,” Pain, vol. 105, no. 1-2, pp. 79–88, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. B. Kraft, N. A. Frickey, R. M. Kaufmann et al., “Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers,” Anesthesiology, vol. 109, no. 1, pp. 101–110, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Narang, D. Gibson, A. D. Wasan et al., “Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy,” Journal of Pain, vol. 9, no. 3, pp. 254–264, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Toth and S. Au, “A prospective identification of neuropathic pain in specific chronic polyneuropathy syndromes and response to pharmacological therapy,” Pain, vol. 138, no. 3, pp. 657–666, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Staud and M. Domingo, “Evidence for abnormal pain processing in fibromyalgia syndrome,” Pain Medicine, vol. 2, no. 3, pp. 208–215, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. J. A. Desmeules, C. Cedraschi, E. Rapiti et al., “Neurophysiologic evidence for a central sensitization in patients with fibromyalgia,” Arthritis and Rheumatism, vol. 48, no. 5, pp. 1420–1429, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. M. C. Rowbotham, “Is fibromyalgia a neuropathic pain syndrome?” Journal of Rheumatology, vol. 32, supplement 75, pp. 38–40, 2005. View at Google Scholar · View at Scopus
  30. F. Wolfe, H. A. Smythe, M. B. Yunus et al., “The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the multicenter criteria committee,” Arthritis and Rheumatism, vol. 33, no. 2, pp. 160–172, 1990. View at Google Scholar · View at Scopus
  31. R. S. Katz, F. Wolfe, and K. Michaud, “Fibromyalgia diagnosis: a comparison of clinical, survey, and American College of Rheumatology criteria,” Arthritis and Rheumatism, vol. 54, no. 1, pp. 169–176, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. D. J. Clauw, “Assessing and diagnosing fibromyalgia in the clinical setting,” The Journal of Clinical Psychiatry, vol. 69, no. 11, article e33, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. M. R. Tramèr, D. Carroll, F. A. Campbell, D. J. M. Reynolds, R. A. Moore, and H. J. McQuay, “Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review,” British Medical Journal, vol. 323, no. 7303, pp. 16–21, 2001. View at Google Scholar · View at Scopus
  34. J. E. Beal, R. Olson, L. Lefkowitz et al., “Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia,” Journal of Pain and Symptom Management, vol. 14, no. 1, pp. 7–14, 1997. View at Publisher · View at Google Scholar · View at Scopus
  35. J. D. Roberts, C. Gennings, and M. Shih, “Synergistic affective analgesic interaction between delta-9- tetrahydrocannabinol and morphine,” European Journal of Pharmacology, vol. 530, no. 1-2, pp. 54–58, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Iskedjian, B. Bereza, A. Gordon, C. Piwko, and T. R. Einarson, “Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain,” Current Medical Research and Opinion, vol. 23, no. 1, pp. 17–24, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. K. B. Svendsen, T. S. Jensen, and F. W. Bach, “Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial,” British Medical Journal, vol. 329, no. 7460, pp. 253–257, 2004. View at Google Scholar · View at Scopus
  38. D. T. Wade, P. Robson, H. House, P. Makela, and J. Aram, “A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms,” Clinical Rehabilitation, vol. 17, no. 1, pp. 21–29, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. D. J. Rog, T. J. Nurmikko, and C. A. Young, “Oromucosal Δ9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial,” Clinical Therapeutics, vol. 29, no. 9, pp. 2068–2079, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. D. J. Rog, T. J. Nurmikko, T. Friede, and C. A. Young, “Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis,” Neurology, vol. 65, no. 6, pp. 812–819, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. W. Seeling, L. Kneer, B. Büchele et al., “?9-tetrahydrocannabinol and the opioid receptor agonist piritramide do not act synergistically in postoperative pain,” Anaesthesist, vol. 55, no. 4, pp. 391–400, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. N. Attal, L. Brasseur, D. Guirimand, S. Clermond-Gnamien, S. Atlami, and D. Bouhassira, “Are oral cannabinoids safe and effective in refractory neuropathic pain?” European Journal of Pain, vol. 8, no. 2, pp. 173–177, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. M. N. Hill and B. B. Gorzalka, “Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test,” European Neuropsychopharmacology, vol. 15, no. 6, pp. 593–599, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. J. M. Witkin, E. T. Tzavara, and G. G. Nomikos, “A role for cannabinoid CB1 receptors in mood and anxiety disorders,” Behavioural Pharmacology, vol. 16, no. 5-6, pp. 315–331, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. G. Marsicano, C. T. Wotjak, S. C. Azad et al., “The endogenous cannabinoid system controls extinction of aversive memories,” Nature, vol. 418, no. 6897, pp. 530–534, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. J. S. Berman, C. Symonds, and R. Birch, “Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial,” Pain, vol. 112, no. 3, pp. 299–306, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. W. S. Marras, S. A. Ferguson, D. Burr, P. Schabo, and A. Maronitis, “Low back pain recurrence in occupational environments,” Spine, vol. 32, no. 21, pp. 2387–2397, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. D. L. Cichewicz, “Synergistic interactions between cannabinoid and opioid analgesics,” Life Sciences, vol. 74, no. 11, pp. 1317–1324, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. D. Viganò, T. Rubino, and D. Parolaro, “Molecular and cellular basis of cannabinoid and opioid interactions,” Pharmacology Biochemistry and Behavior, vol. 81, no. 2, pp. 360–368, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. T. S. Jensen and N. B. Finnerup, “Management of neuropathic pain,” Current Opinion in Supportive and Palliative Care, vol. 1, no. 2, pp. 126–131, 2007. View at Google Scholar · View at Scopus
  51. E. Palazzo, I. Marabese, V. de Novellis et al., “Metabotropic and NMDA glutamate receptors participate in the cannabinoid-induced antinociception,” Neuropharmacology, vol. 40, no. 3, pp. 319–326, 2001. View at Publisher · View at Google Scholar · View at Scopus